Crispr Therapeutics Ag (CRSP)
$37.91 0.16 (0.42%)
17:35 EDT CRSP Stock Quote Delayed 15 Minutes
Previous Close $37.91
Market Cap 1.78B
PE Ratio -
Volume (Avg. Vol.) 282,700
Day's Range 37.72 - 38.45
52-Week Range 22.22 - 53.90
Dividend & Yield N/A (N/A)
CRSP Stock Predictions, Articles, and Crispr Therapeutics Ag News
- From InvestorPlace
- From the Web
Uncertainty is a constant risks for biotech stocks. Which ones matter? Some are down so much investors cannot ignore them now.
Government is scrutinizing the drug development and approval process and creating uncertainties among biotech stocks. Time to buy?
InVitae, Crispr and Myriad are just some of the genomic testing stocks worth a look as DNA becomes a more important part of healthcare.
Over the long term, gene therapy stocks will head higher and the last few weeks' of headlines show investors why.
CRSP is testing its gene editing therapies in sicke cell disease and cancer. These therapies could eventually boost CRSP stock.
If you're looking for biotech stocks to buy with massive breakthrough potential in gene editing, then these three are kings among the rest.
Even by biotech standards, CRSP stock is volatile and prone to snap reactions -- but the potential rewards are huge.
These three high-reward stocks, each with their own emerging trend, that have huge upside potential in the transformative years ahead.
Crispr stock is down 7% on the release of a new study. But the headline is not nearly as scary as it sounds.
Although Crispr’s gene splicing techniques are revolutionary, the rally in CRSP stock is coming to an end as investors question its valuation.
Though the biotech industry is down this year, there are still a few stocks which can strengthen your portfolio. Compare Brokers....
These 4 names are the best stocks to buy right now, each offering something most other stocks don't.
Crispr stock is riding a euphoric wave thanks to the biotech firm’s innovations. But what is CRISPR and what are the downsides?
From Analyst Ratings
Chardan Capital analyst Geulah Livshits reiterated a Buy rating on Crispr Therapeutics AG (CRSP – Research Report) today and set a price target of $72.50. The company’s shares closed last Monday at $37.96. According to TipRanks.com, Livshits is ranked 0 out of 5 stars with an average return of -14.1% and a 20.7% success rate.
From Market News Video
Investors in CRISPR Therapeutics AG (CRSP) saw new options become available this week, for the November 22nd expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the CRSP options chain for the new November 22nd contracts and identified one put and one call contract of particular interest.
Navellier RatingsPowered by Portfolio Grader
10 Stocks Set for Monster Growth
He found Apple at $4… Oracle at $6… Amazon at $40… Now legendary growth investor Louis Navellier is giving away his latest Research Report — for FREE!
Download your FREE COPY!